¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29
±³À°ÀÏÀÚ : 2020-02-29
±³À°Àå¼Ò : ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ  
±³À°ÁÖÁ¦ : ¸Á¸·
ÁÖÃÖ±â°ü : ´ë±¸°¡Å縯´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú  
´ã´çÀÚ : À̽ÃÀº
¿¬¶ôó : 053-650-4728  
À̸ÞÀÏ : dcmc_ot@naver.com      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í »çÀüµî·Ï- Àü¹®ÀÇ 50,000¿ø, Àü°øÀÇ 40,000¿ø ÇöÀåµî·Ï- Àü¹®ÀÇ 60,000¿ø, Àü°øÀÇ 50,000¿ø °èÁ¹øÈ£ 508-13-827509-5(´ë±¸ÀºÇà, ¹é¹ÎÁÖ)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:20~09:30 Multimodal imaging of type 1,2,3 CNV  Á¤Àοµ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:30~09:40 Clinical application of OCTA in ARMD and its allied disease  ÀÌÁÖ¿ë(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:40~09:50 Clinical application of OCTA in DMR and BRVO  ¹Úµ¿È£(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:50~10:00 Clinical value of wide FP and FA and ICG  »ç°ø¹Î(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:00~10:10 Enface OCT imaging  ¾È¼ºÁØ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:10~10:20 AF imaging in retinal field  À¯½Â¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:20~10:30 Imaging of choroid  ¹Ú¼ºÇ¥(ÇѸ²ÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:30~10:45 DIscussion  () 
È޽Ġ02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:45~11:05 Break  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:05~11:15 Classification of various drusen  ±èÀ¯Ã¶(°è¸íÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:15~11:25 Dry ARMD treatment, present and emerging  ±èÇö¿õ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:25~11:35 Risk factor of geographic atrophy secondary to ARMD  ÃÖ°æ½Ä(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:35~11:45 Update of pachychoroid diseases  ÀÌ¿ø±â(´©³×¾È°úº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:45~11:55 Treatment of wet ARMD and PCV, experience and future  °íÇüÁØ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:55~12:05 Myopic CNV, treatment and DDX  ½ÅÀçÇÊ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:05~12:15 Mactel type 2 current concept  ¿ÀÀç·É(°í·ÁÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:15~12:30 DIscussion  () 
½Ä»ç 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:30~13:30 Lunch time  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 13:30~14:00 ±è½Ãµ¿ ±³¼ö ¼Ò°³ ¹× Ưº° °­¿¬  ±è½Ãµ¿(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:00~14:10 Lessons from DRCR.net protocol I, S, T  ¼ÛÁöÈÆ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:10~14:20 Brief summary of ongoing DRCR.net protocol U, V, W  À̽¿ì(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:20~14:30 Anti VEGF in DME  Á¶¿µÁØ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:30~14:40 Steroid role in DME  ÀÌÁ¾Çö(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:40~14:50 Managenet of refractory DME and DMR progression in real practice  ÁøÈñ½Â(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:50~15:00 Endophthalmitis after intravitreal injection  ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:00~15:10 Current management of vein occlusion  ³²µ¿Èç(°¡ÃµÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:10~15:25 Discussion  () 
È޽Ġ02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:25~15:40 Break  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:40~15:50 Vitrectomy for RRD(case slection, tamponade, etc)  ±èö±¸(±è¾È°úº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:50~16:00 Vitrectomy for ERM(good vision caes, inner lamellar hole)  ±èÀ±¿µ(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:00~16:10 Vitrectomy for IOL dislocation(various method)  ±è¼º¼ö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:10~16:20 Vitrectomy for macular hole(conventional/flap, prone, tmponade, etc)  ÀÌÁöÀº(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:20~16:30 Vitrectomy for uveitis(what cases, combine treatment, etc)  À¯Çü°ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:30~16:40 Vitrectomy for DMR(how to improve result, adjuvant, etc)  ±èÁß°ï(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:40~16:50 3D surgery(merits and limitation)  ¹Ú±ÔÇü(¼­¿ïÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:50~17:05 Discussion  () 
±âŸ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 17:05~17:10 Closing  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ °Ç°­º¸Çè ºòµ¥ÀÌÅÍ ÀÚ·áºÐ¼®À» ÅëÇÑ ³í¹®Ãâ°£ ¿öÅ©¼¥ : 2020-02-29
´ÙÀ½±Û Á¦ 6ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì: 2020-02-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
294 °æ±â ´ëÇÑ°³¿øÀÇÇùÀÇȸ °­¿øÁöȸ ½ÉÆ÷Áö¿ò : 2018-08-18 0 622 2018-08-08
293 ¼­¿ï ´ëÇÑÈäºÎ¿Ü°úÇÐȸ Heart Valve Disease Symposium 2018 : 2018-08-17 0 1,086 2018-08-08
292 ¼­¿ï °æÈñ´ëÇб³º´¿ø Á¦11ȸ »êºÎÀΰú-¼Ò¾Æû¼Ò³â°ú ¼±»ý´Ôµé°ú ÇÔ²²ÇÏ´Â ¿ù·ÊÁý´ãȸ : 2018-08-17 0 915 2018-08-08
291 °­¿ø °­¿øµµÀÇ»çȸ ÀúÇ÷´çÁõ¿¡ ´ëÇÑ °íÂû : 2018-08-16 0 553 2018-08-08
290 ¼­¿ï ´ëÇѽÅÀåÇÐȸ 2018 Update on CKD-MBD: Phosphorous and Magnesium in health and disease : 2018-09-30 0 1,150 2018-07-28
289 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ ¼Ò¾ÆÁúȯ : 2018-09-29 0 856 2018-07-28
288 ¼­¿ï 2018 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : ¿¬±Ø¼º ÀΰÝÀå¾Ö, ÀÇÁ¸¼º ÀΰÝÀå¾Ö : 2018-09-29 0 1,235 2018-07-28
287 ¼­¿ï 2018 ´ëÇÑâ»óÇÐȸ ±³À°½ÉÆ÷Áö¾ö : 2018-09-29 0 621 2018-07-28
286 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(CSC treatment update) : 2018-09-28 0 1,103 2018-07-28
285 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) ÇǺΠÇ÷°ü Áúȯ 2) »ö¼Ò ÀÌ»óÁõ : 2018-09-27 0 775 2018-07-28
284 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª(Æó¼â°¢ ³ì³»Àå) : 2018-09-21 0 1,427 2018-07-28
283 ´ë±¸ ´ëÇѽÅÀåÇÐȸ ´ë±¸-°æºÏÁöȸ ¿¬¼ö °­Á : 2018-09-20 0 668 2018-07-28
282 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-20 0 393 2018-07-28
281 ¼­¿ï [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] 4Â÷ »ê¾÷Çõ¸í°ú ÀÇ·áÀÇ ¹Ì·¡ : 2018-09-20 0 644 2018-07-28
280 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ Á¦5Â÷ ȸ¿ø¿¬¼ö±³À°(Áø´Ü¸í¿¡ µû¸¥ ÀûÀýÇÑ Ã³¹æ) : 2018-09-20 0 852 2018-07-28
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷